Clinical trial
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With…
NCT00241514 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00241514 |
|---|---|
| Title | Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs |
| Official title | Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | GERD |
| Intervention type | Drug |
| Interventions | Esomeprazole |
| Enrollment | 334 |
| Start date | Feb 1, 2001 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | Oct 19, 2005 |
| Last update posted | Jan 21, 2011 |
| Countries | Belgium, France, Germany, Hungary, Spain, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: